Individuals with neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) should remain on immunosuppressants to prevent severe relapse and are recommended to practice personal protective measures to reduce the risk of coronavirus disease 2019 (COVID-19) infections.
Why this matters ?
There has been little information on how COVID-19 affects individuals with pre-existing neurological conditions such as NMOSD or MOGAD. Nearly all individuals with NMOSD are treated with immunosuppressive therapies which may alter the severity of the coronavirus infection. The results of this study increase the understanding of how individuals with NMOSD or MOGAD may be affected by a COVID-19 infection.